A new drug for Hunter syndrome, the Ado sulfate enzyme beta injection, has been approved in China.

On September 3rd, Noah Pharmaceuticals/Beihai Kangcheng filed an application for the listing of Adolfate beta injections in China, which was approved by the State Drug Administration for the treatment of Hunter syndrome.
Hunt syndrome, also known as type II mucosal polysaccharide storing disorder, is a rare, disabling, and fatal genetic disorder caused by a lack of 2-sulphatease, an enzyme necessary to break down glycosamine (GAGs) in the body.
deficiency of 2-sulphate enzymes can lead to the accumulation of GAG in patients and lead to serious bone, tissue, nerve and multi-organ complications, which can eventually lead to death.
is more common in East Asia and is currently incurable, with standard therapy being enzyme replacement therapy or palliative care.
Ado sulfate enzyme beta (English trade name: Hunterase) is a recombinant person Adulystic acid-2-sulphate enzyme replacement therapy, developed by GC Pharma, Beihai Kangcheng owns the Chinese interest in the drug.
source: Medical Rubik's Cube!-- the end of the content display -- !-- determine whether the login is over.